Alternative splicing of BCL-X and implications for treating hematological malignancies

BCL-X is a member of the BCL-2 family. It regulates apoptosis and plays a critical role in hematological malignancies. It is well-known that >90% of human genes undergo alternative splicing. A total of 10 distinct splicing transcripts of the BCL-X gene have been identified, including transcript v...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wanling, Li, Jinggang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323006/
https://www.ncbi.nlm.nih.gov/pubmed/34345295
http://dx.doi.org/10.3892/ol.2021.12931
_version_ 1783731161136103424
author Chen, Wanling
Li, Jinggang
author_facet Chen, Wanling
Li, Jinggang
author_sort Chen, Wanling
collection PubMed
description BCL-X is a member of the BCL-2 family. It regulates apoptosis and plays a critical role in hematological malignancies. It is well-known that >90% of human genes undergo alternative splicing. A total of 10 distinct splicing transcripts of the BCL-X gene have been identified, including transcript variants 1–9 and ABALON. Different transcripts from the same gene have different functions. The present review discusses the progress in understanding the different alternative splicing transcripts of BCL-X, including their characteristics, functions and expression patterns. The potential use of BCL-X in targeted therapies for hematological malignancies is also discussed.
format Online
Article
Text
id pubmed-8323006
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-83230062021-08-02 Alternative splicing of BCL-X and implications for treating hematological malignancies Chen, Wanling Li, Jinggang Oncol Lett Review BCL-X is a member of the BCL-2 family. It regulates apoptosis and plays a critical role in hematological malignancies. It is well-known that >90% of human genes undergo alternative splicing. A total of 10 distinct splicing transcripts of the BCL-X gene have been identified, including transcript variants 1–9 and ABALON. Different transcripts from the same gene have different functions. The present review discusses the progress in understanding the different alternative splicing transcripts of BCL-X, including their characteristics, functions and expression patterns. The potential use of BCL-X in targeted therapies for hematological malignancies is also discussed. D.A. Spandidos 2021-09 2021-07-18 /pmc/articles/PMC8323006/ /pubmed/34345295 http://dx.doi.org/10.3892/ol.2021.12931 Text en Copyright: © Chen et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Chen, Wanling
Li, Jinggang
Alternative splicing of BCL-X and implications for treating hematological malignancies
title Alternative splicing of BCL-X and implications for treating hematological malignancies
title_full Alternative splicing of BCL-X and implications for treating hematological malignancies
title_fullStr Alternative splicing of BCL-X and implications for treating hematological malignancies
title_full_unstemmed Alternative splicing of BCL-X and implications for treating hematological malignancies
title_short Alternative splicing of BCL-X and implications for treating hematological malignancies
title_sort alternative splicing of bcl-x and implications for treating hematological malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323006/
https://www.ncbi.nlm.nih.gov/pubmed/34345295
http://dx.doi.org/10.3892/ol.2021.12931
work_keys_str_mv AT chenwanling alternativesplicingofbclxandimplicationsfortreatinghematologicalmalignancies
AT lijinggang alternativesplicingofbclxandimplicationsfortreatinghematologicalmalignancies

Ejemplares similares